Komori
Other Disclosures4544H.U. Group Holdings,Inc.Information and communications, services and other

Regarding the acquisition of Japanese marketing approval for a blood-based β-amyloid 1-42 assay reagent that assists in assessing brain amyloid-β accumulation associated with Alzheimer's disease

Fujirebio Co., Ltd. has obtained marketing approval in Japan for an assay reagent that measures plasma β-amyloid 1-42 and assists in assessing brain amyloid-β accumulation associated with Alzheimer's disease.

Worth reading
52Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

LUMIPULSE β-Amyloid 1-42-N (Plasma)Fully automated chemiluminescent enzyme immunoassay system LUMIPULSE® G1200Fully automated chemiluminescent enzyme immunoassay system LUMIPULSE® G600II
Applicable field (uses covered by this announcement)

Assisting in assessing brain amyloid-β accumulation associated with Alzheimer's disease

Relationship between the counterparty and the company
H.U. Group Holdings,Inc.4544
Relationship with the Company

The Ministry of Health, Labour and Welfare is the approval authority for products for which Fujirebio Co., Ltd. obtains marketing approval. Fujirebio Co., Ltd. is a company under Fujirebio Holdings, Inc., a consolidated subsidiary of our company.

CounterpartyMinistry of Health, Labour and Welfare

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

Ministry of Health, Labour and Welfare

Announced details
ItemDetails
Names of Products / Services CoveredLUMIPULSE β-Amyloid 1-42-N (Plasma), Fully automated chemiluminescent enzyme immunoassay system LUMIPULSE® G1200, Fully automated chemiluminescent enzyme immunoassay system LUMIPULSE® G600II
CounterpartyMinistry of Health, Labour and Welfare
Relationship with the CompanyThe Ministry of Health, Labour and Welfare is the approval authority for products for which Fujirebio Co., Ltd. obtains marketing approval. Fujirebio Co., Ltd. is a company under Fujirebio Holdings, Inc., a consolidated subsidiary of our company.
Applicable areaAssisting in assessing brain amyloid-β accumulation associated with Alzheimer's disease
SourceMinistry of Health, Labour and Welfare
Items this document does not state (13)
Counterparty overviewContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

As part of efforts to expand the product lineup in the neurodegenerative disease field to support the diagnosis and treatment of Alzheimer's disease.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Regarding the acquisition of Japanese marketing approval for a blood-based β-amyloid 1-42 assay reagent that assists in assessing brain amyloid-β accumulation associated with Alzheimer's disease | H.U. Group Holdings,Inc. (4544) timely disclosure | Komori